These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 18992242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
    Sharif NA.
    Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
    [Abstract] [Full Text] [Related]

  • 3. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist.
    Sharif NA, McLaughlin MA, Kelly CR.
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):1-13. PubMed ID: 17341144
    [Abstract] [Full Text] [Related]

  • 4. FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys.
    Sharif NA, Katoli P, Scott D, Li L, Kelly C, Xu S, Husain S, Toris C, Crosson C.
    Drug Dev Res; 2014 Jun; 75(4):211-23. PubMed ID: 24796320
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule.
    Sharif NA, Li L, Katoli P, Xu S, Veltman J, Li B, Scott D, Wax M, Gallar J, Acosta C, Belmonte C.
    Exp Eye Res; 2014 Nov; 128():170-80. PubMed ID: 25307520
    [Abstract] [Full Text] [Related]

  • 6. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G, Carreiro S, Anderson S, Gukasyan H, Sartnurak S, Younis H, Gale D, Xiang C, Wells P, Dinh D, Almaden C, Fortner J, Toris C, Niesman M, Lafontaine J, Krauss A.
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [Abstract] [Full Text] [Related]

  • 7. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
    Sharif NA, McLaughlin MA, Kelly CR, Xu S, Crider JY, Williams GW, Parker JL.
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
    Nilsson SF, Drecoll E, Lütjen-Drecoll E, Toris CB, Krauss AH, Kharlamb A, Nieves A, Guerra T, Woodward DF.
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate).
    Pang IH, Moll H, McLaughlin MA, Knepper PA, De Santis L, Epstein DL, Clark AF.
    Exp Eye Res; 2001 Dec; 73(6):815-25. PubMed ID: 11846512
    [Abstract] [Full Text] [Related]

  • 12. Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline.
    Platania CB, Leggio GM, Drago F, Salomone S, Bucolo C.
    Biochem Pharmacol; 2013 Nov 01; 86(9):1347-56. PubMed ID: 23962442
    [Abstract] [Full Text] [Related]

  • 13. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
    Woodward DF, Nilsson SF, Toris CB, Kharlamb AB, Nieves AL, Krauss AH.
    Invest Ophthalmol Vis Sci; 2009 Jul 01; 50(7):3320-8. PubMed ID: 19234340
    [Abstract] [Full Text] [Related]

  • 14. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E.
    Exp Eye Res; 2011 Sep 01; 93(3):250-5. PubMed ID: 21396362
    [Abstract] [Full Text] [Related]

  • 15. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
    Stankowska DL, Millar JC, Kodati B, Behera S, Chaphalkar RM, Nguyen T, Nguyen KT, Krishnamoorthy RR, Ellis DZ, Acharya S.
    Mol Vis; 2021 Sep 01; 27():37-49. PubMed ID: 33633438
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
    Savinainen A, Prusakiewicz JJ, Oswald J, Spencer E, Lou Z, Cohen ML, Rashidzadeh H, Josiah S.
    Exp Eye Res; 2019 Dec 01; 189():107836. PubMed ID: 31626797
    [Abstract] [Full Text] [Related]

  • 17. Effects of travoprost on aqueous humor dynamics in monkeys.
    Toris CB, Zhan GL, Camras CB, McLaughlin MA.
    J Glaucoma; 2005 Feb 01; 14(1):70-3. PubMed ID: 15650608
    [Abstract] [Full Text] [Related]

  • 18. Human non-pigmented ciliary epithelium bradykinin B2-receptors: receptor localization, pharmacological characterization of intracellular Ca(2+) mobilization, and prostaglandin secretion.
    Sharif NA, Wang Y, Katoli P, Xu S, Kelly CR, Li L.
    Curr Eye Res; 2014 Apr 01; 39(4):378-89. PubMed ID: 24624903
    [Abstract] [Full Text] [Related]

  • 19. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
    Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AH.
    Invest Ophthalmol Vis Sci; 2015 Oct 01; 56(11):6558-64. PubMed ID: 26457541
    [Abstract] [Full Text] [Related]

  • 20. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
    Prasanna G, Fortner J, Xiang C, Zhang E, Carreiro S, Anderson S, Sartnurak S, Wu G, Gukasyan H, Niesman M, Nair S, Rui E, Lafontaine J, Almaden CD, Wells P, Krauss A.
    Exp Eye Res; 2009 Nov 01; 89(5):608-17. PubMed ID: 19445930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.